Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks [PDF]
, 2019 Anaïs Corma‐Gómez +10 more
openalex +1 more source
Short-Term Clinical and Immunologic Outcomes Conditional on SVR12 in Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Treated With Direct-Acting Antivirals: A Systematic Review and Meta-Analysis. [PDF]
CureusBoonpheng B, Ungprasert P.
europepmc +1 more source
Consideration of ledipasvir/sofosbuvir as an alternative to glecaprevir/pibrentasvir based upon on-treatment FIB-4 changes and sustained virologic response at 12 weeks in hepatitis C genotype 1 and 2 infections: A propensity score-matched study. [PDF]
Medicine (Baltimore)Park HJ +5 more
europepmc +1 more source
Efficacy and safety of sofosbuvir-based therapies for treating HCV in children: observations from a real-world setting. [PDF]
Eur J Clin Microbiol Infect DisPokorska-Śpiewak M +4 more
europepmc +1 more source
Sofosbuvir and ledipasvir for HIV/HCV co-infected patients
, 2016 Elana Rosenthal +2 more
openalex +2 more sources
P1‐068: Hepatitis C treatment with Ledipasvir and Sofosbuvir in a low socioeconomic population at a Federally Qualified Health Center [FQHC] [PDF]
, 2018 openalex +1 more source
Sensitive RP-HPLC method with fluorimetric detection for concurrent quantification of emtricitabine, Daclatasvir and Ledipasvir in human urine. [PDF]
Sci RepYoussef AA +3 more
europepmc +1 more source
P1‐071: Efficacy of Ledipasvir/Sofosbuvir in Egyptian adolescents with hepatitis C virus genotype 4; a single center study [PDF]
, 2018 openalex +1 more source